High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes.

Leukemia & Lymphoma
Bei HuMuzaffar H Qazilbash

Abstract

The aim of our study was to determine the impact of high-risk disease (HRD) and MRD on outcomes in myeloma patients receiving bortezomib-based induction followed by autologous hematopoietic stem cell transplant (auto-HSCT). HRD included t(4:14), t(14;16), del 17p, del 1p and/or amplification 1q by cytogenetics/FISH; all others were standard-risk disease (SRD). A subset of 165 newly diagnosed myeloma patients in a 2:1 ratio of HRD:SRD was generated using propensity score based nearest neighbor matching. Multiparametric flow cytometry (MFC) was used to detect MRD after auto-HSCT in select patients. MRD+ status at 3 months post auto-HSCT (hazard ratio (HR = 4.23, p = .028) and HRD (HR = 1.72, p = .026) were associated with a shorter PFS. Similarly, MRD+ 3 months post auto-HSCT (HR = 6.93, p = .08) and HRD (HR = 3.54, p < .001) and were associated with a shorter OS. Despite bortezomib-based induction, upfront auto-HSCT, and use of maintenance therapy, PFS and OS remained worse in MRD+ and HRD patients.

References

May 9, 2003·The New England Journal of Medicine·J Anthony ChildUNKNOWN Medical Research Council Adult Leukaemia Working Party
Feb 24, 2005·British Journal of Haematology·Roger G Owen, Andy C Rawstron
Mar 10, 2006·The New England Journal of Medicine·Bart BarlogieJohn Crowley
Jul 29, 2006·Blood·Michel AttalUNKNOWN Inter-Groupe Francophone du Myélome (IFM)
Feb 13, 2008·Haematologica·Andy C RawstronUNKNOWN European Myeloma Network
Aug 2, 2008·Blood·Bruno PaivaUNKNOWN GEM (Grupo Español de MM)/PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) Cooperative Study Grou
Nov 13, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Juan José LahuertaJesús F San Miguel
Jul 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hervé Avet-LoiseauJean-Luc Harousseau
Jan 18, 2011·Hematology·Hervé Avet-Loiseau
Sep 10, 2011·British Journal of Haematology·Susanna J JacobusRafael Fonseca
Oct 1, 2011·Genes, Chromosomes & Cancer·Kevin D BoydUNKNOWN NCRI Haematology Oncology Studies Group
Oct 14, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kevin D BoydUNKNOWN NCRI Haematology Oncology Studies Group
Oct 25, 2011·Blood·Gareth J MorganUNKNOWN National Cancer Research Institute Haematological Oncology Clinical Studies Group
Dec 1, 2011·Blood·Bruno PaivaUNKNOWN PETHEMA/GEM (Programa para el Estudio de la Terapéutica en Hemopatías Malignas/Grupo Español de Mieloma) Cooperative Study G
May 11, 2012·The New England Journal of Medicine·Philip L McCarthyCharles Linker
May 11, 2012·The New England Journal of Medicine·Michel AttalUNKNOWN IFM Investigators
Jun 23, 2012·Leukemia·R KuiperP Sonneveld
Jul 14, 2012·Blood·Laura RosiñolUNKNOWN Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group
Jul 18, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Pieter SonneveldHartmut M Goldschmidt
Jun 5, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andy C RawstronRoger G Owen
Aug 27, 2013·Leukemia·W J ChngUNKNOWN International Myeloma Working Group
Nov 20, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Prashant KapoorMorie A Gertz
Sep 4, 2014·The New England Journal of Medicine·Antonio PalumboMichele Cavo
Sep 13, 2014·Hematology/oncology Clinics of North America·Philip L McCarthy, Antonio Palumbo
Mar 11, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Bruno PaivaUNKNOWN Grupo Español de Mieloma (GEM)/Programa para el Estudio de la Terapéutica en Hemopatías Malignas (PETHEMA) cooperative study

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Risk Prediction

Cardiovascular risk prediction models based on classical risk factors identified in epidemiological studies are useful in primary prevention of cardiovascular disease in individuals. Here is the latest research.

CNS Lymphoma

In CNS lymphoma, cancerous cells from lymph tissues or other parts of the body form tumors in the brain and/or spinal cord. Here is the latest research on this rare non-Hodgkin lymphoma.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cardiovascular Diseases: Risk Factors

Cardiovascular disease is a significant health concern. Risk factors include hypertension, obesity, dyslipidemia and smoking. Women who are postmenopausal are at an increased risk of heart disease. Here is the latest research for risk factors of cardiovascular disease.